Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 09:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors

Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at...
April 20, 2026 08:35 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I...
April 09, 2026 08:50 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC

CEO Abizer Gaslightwala discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development acceleration Company highlights accelerated IND...
April 06, 2026 08:45 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing

TAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA...
March 18, 2026 08:05 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026

TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice...
March 17, 2026 16:30 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces ADS Ratio Change

TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice...
March 13, 2026 09:15 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala

Highlights strategic progress achieved under Abizer Gaslightwala’s leadership, including advancement of AKTX-101 and expansion of Akari’s ADC pipeline Access the Akari CEO Corner here TAMPA, Fla....
February 26, 2026 09:10 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board

TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel...
February 23, 2026 08:50 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel...
February 18, 2026 09:05 ET | Source: Akari Therapeutics Plc

Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference

TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel...